Filing Summary
Registrant: Blue Water Biotech, Inc. (the request metadata identifies Onconetix, Inc.; the filing itself names Blue Water Biotech, Inc.)
Form 8-K date: May 10, 2023. The filing reports a Regulation FD disclosure and furnishes a related press release.
Business Context and Reporting Period
Management announced its planned presentation at the JMP Securities Life Sciences Conference in New York on May 15, 2023, at 3:30 p.m. EDT. This 8-K is not a quarterly or annual financial report and does not provide a financial reporting-period update.
Financial and Operating Metrics
- Revenue, profit or loss, cash flow, margins, debt, liquidity, and other financial metrics are not provided in the filing text.
- No new financial statements or material operating results were reported.
Material Changes Versus Prior Period
The filing does not disclose material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance, forecast, or outlook was provided.
- No new risks, contingencies, financings, acquisitions, or unusual accounting items were disclosed.
- The presentation announcement was furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other SEC filings.
Important Facts to Verify
- Verify the registrant identity, as the source filing names Blue Water Biotech, Inc., while the request metadata names Onconetix, Inc.
- Review Exhibit 99.1 for the full conference announcement and any additional management commentary.
- Consult the company’s latest periodic filing for financial condition, liquidity, operating results, and risk disclosures, none of which are included here.